-
Mediator kinase inhibition reverses castration resistance of advanced prostate cancer.
24 Apr 2024 08:24 GMT
… are upregulated in castration-resistant prostate cancer (CRPC). Genetic or … the sensitivity of CRPC xenografts to androgen deprivation in … the growth of CRPC xenografts but also induces tumor … efficacy in patient-derived xenograft models of CRPC, and …
-
Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer.
23 Apr 2024 11:53 GMT
… metastatic castration-resistant prostate cancer. Here we introduce … - and patient-derived prostate cancer xenograft models. The antitumor … and patient-derived (ST1273) xenograft models.
These results provide … in patients with prostate cancer. A clinical phase …
-
Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside.
23 Apr 2024 11:53 GMT
Management of prostate cancer (PC) might be improved by … -617 in a murine PC xenograft model. Finally, a clinical case …
-
BET inhibitors as a therapeutic intervention in gastrointestinal gene signature-positive castration-resistant prostate cancer.
19 Apr 2024 10:04 GMT
A subgroup of castration-resistant prostate cancer (CRPC) aberrantly expresses a … derived organoids, and patient-derived xenografts, while AR and the … transcriptome-positive preclinical models of prostate cancer. Mechanistically, BETi inhibited BRD4 …
-
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
18 Apr 2024 22:39 GMT
… application of light therapy.
Using prostate cancer cells, the group first inactivated … . Moreover, human cancer cell xenografts require immunodeficient mice. We hypothesize … obtained by using syngeneic mouse prostate tumors should allow the recruitment …
-
MD Anderson Research Highlights for April 24, 2024
24 Apr 2024 16:22 GMT
… molecular mechanisms of prostate cancer, the role … Communications.
Comprehensive prostate cancer platform serves as … therapeutic strategies
Metastatic prostate cancer that is … xenograft (PDX) models from 38 patients with various stages of prostate cancer …
-
Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer
08 Apr 2024 12:48 GMT
… ), was then evaluated in 22Rv1 prostate tumor xenograft models and compared to the … precision medicine for men with prostate cancer. Radiohybrid technology and rhPSMA originated … emerging pipeline, initially focused on prostate cancer, and with plans to expand …
-
CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality.
03 Apr 2024 12:11 GMT
… subtype of metastatic castration-resistant prostate cancer (mCRPC). It remains unclear … positive, luminal prostate cancer. Notably, Cdk12/Trp53 loss prostate tumors are sensitive … ablation) and patient-derived xenografts from tumors with CDK12 …
-
Senex Publication Reveals the Importance of CDK8/19 Inhibition as Treatment for Castration Resistant Prostate Cancer
02 Apr 2024 12:00 GMT
… for Castration Resistant Prostate Cancer
Senex Biotechnology … , in castration resistant prostate cancer (CRPC). (Mediator … sensitivity of CRPC xenografts to androgen deprivation … of clinical prostate cancers, genetic modifications of prostate cancer cells, …
-
A Novel DNA Aptamer Probe Recognizing Castration Resistant Prostate Cancer in vitro and in vivo Based on Cell-SELEX
18 Mar 2024 13:17 GMT
… to establish the prostate tumor-bearing model with … castration resistant prostate cancer; ADPC represents androgen dependent prostate cancer. Scale … C4-2 CRPC xenograft tumor model and … -resistant prostate cancer-like cells in primary prostate cancer promote …